Investigating the role of TBX20 in heart cell development
Critical Role of TBX20 in Cardiomyocyte Maturation during Direct Cardiac Reprogramming
['FUNDING_R01'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-10662347
This study is looking at how a special factor called TBX20 can help turn skin cells into heart cells more effectively, which could lead to better treatments for heart failure.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-10662347 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the process of converting fibroblasts into heart cells, known as induced cardiomyocytes (iCMs), which could be a new treatment for heart failure. The study aims to understand how a specific factor, TBX20, influences the maturation of these heart cells by regulating important gene programs. By enhancing the efficiency and quality of iCM generation from human cells, the research seeks to overcome current limitations faced in cardiac reprogramming. Patients may benefit from advancements in heart failure therapies through this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with heart failure or those at risk of developing heart-related conditions.
Not a fit: Patients with non-cardiac related health issues or those who do not have heart failure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for heart failure by improving the generation of heart cells from patients' own fibroblasts.
How similar studies have performed: Previous research has shown promise in similar approaches to cardiac reprogramming, but this specific focus on TBX20 is relatively novel.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHOU, YANG — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: ZHOU, YANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.